The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INO | -59.41% | -98.27% | -55.59% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +470% |
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Can the biotech succeed after a string of failures?
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.74M | -1.9% |
| Gross Margin | -1037.77% | 0.0% |
| Market Cap | $74.63M | -64.4% |
| Market Cap / Employee | $0.56M | 0.0% |
| Employees | 134 | 9.8% |
| Net Income | -$23.52M | 27.0% |
| EBITDA | -$22.34M | 31.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $24.35M | -29.2% |
| Accounts Receivable | $0.84M | -52.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.00M | -24.9% |
| Short Term Debt | $2.66M | 14.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -86.88% | -20.6% |
| Return On Invested Capital | -91.64% | -3.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.84M | 27.3% |
| Operating Free Cash Flow | -$20.81M | 26.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.55 | 0.65 | 0.86 | 1.46 | -27.17% |
| Price to Sales | 799.61 | 272.78 | 222.33 | 433.37 | 16.72% |
| Price to Tangible Book Value | 1.55 | 0.65 | 0.86 | 1.46 | -27.17% |
| Enterprise Value to EBITDA | -3.40 | 1.17 | -0.24 | -1.89 | -50.10% |
| Return on Equity | -106.6% | -115.4% | -132.4% | -140.1% | 53.26% |
| Total Debt | $12.45M | $11.87M | $11.27M | $10.66M | -17.89% |
INO earnings call for the period ending December 31, 2024.
INO earnings call for the period ending September 30, 2024.
INO earnings call for the period ending June 30, 2024.
INO earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
